The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

Created in 1992, the 340B Drug Pricing Program is a U.S. federal government program intended to give safety net providers—those that organize and deliver a significant level of both healthcare and ...

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...

On July 31, 2025, the Department of Health and Human Services (HHS) announced a much-anticipated 340B Rebate Model Pilot Program (Pilot Program) via guidance (Guidance) that will be formally published ...

The Trump administration's attempt to overhaul how safety net hospitals pay for outpatient drugs has run into a major legal ...

Commercial: Is the 340B Drug Pricing Program the Next 'Too Big to Fail'? WASHINGTON, Aug. 19, 2025 /PRNewswire/ -- ADAP Advocacy today, as part of its 340B Project, aired its latest commercial calling ...

Joe Grogan is a Nonresident Senior Scholar at the USC Schaeffer Institute and served as director of the White House Domestic ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...

Regarding “New Jersey hospitals exploit 340B at the expense of patients,” NorthJersey.com, Jan. 17: Everyone can relate to the high price of prescription drugs — including hospitals, which, like ...

The 340B Drug Pricing Program (340B Program) is no stranger to controversy. We have previously covered the ongoing contract pharmacy legal battles and the new alternative dispute resolution process.

The pharmaceuticals lobby shored up its campaign against increasing use of the 340B Drug Discount Program with a new analysis estimating its broader use pulled $6.5 billion in rebates away from the ...